Related Experiment Video
Updated: Jun 10, 2026
08:00
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
Published on: April 16, 2019
Multidisciplinary approach for advanced stage thymic tumors: long-term outcome
Federico Rea1, Giuseppe Marulli, Francesco Di Chiara
1Department of Cardio-Thoracic and Vascular Sciences, Division of Thoracic Surgery, University of Padova, Italy.
Lung Cancer (Amsterdam, Netherlands)
|August 17, 2010
Summary
Multimodality treatment for advanced thymic tumors improves outcomes. Complete resection and specific histotypes predict better survival, with acceptable recurrence rates.
Area of Science:
- Oncology
- Thoracic Surgery
- Cancer Treatment
Background:
- Advanced stage thymic tumors often present challenges for complete surgical resection.
- Multimodality treatment is increasingly recognized for improving resectability and reducing recurrence in thymic malignancies.
Purpose of the Study:
- To evaluate the efficacy of multimodality treatment for advanced stage thymic tumors (Stages III-IVB).
- To identify factors influencing resectability, survival, and recurrence rates in this patient cohort.
Main Methods:
- Retrospective analysis of 75 patients with Stages III-IVB thymic tumors treated between 1980-2008.
- Patients received induction chemotherapy, surgery, and postoperative radiotherapy/chemoradiotherapy.
- Histopathological subtypes (A-AB-B1 vs. B2-B3-C) and resection status (complete vs. incomplete) were analyzed.
Main Results:
- Complete resection (CR) was achieved in 81.3% of patients.
- Ten-year survival was significantly better for CR (62% vs. 28%) and for histotype A-AB-B1 (60% vs. 53%).
- Induction chemotherapy did not significantly impact 10-year survival (52% vs. 56%).
Conclusions:
- Multimodality treatment offers effective disease control for advanced thymic tumors.
- Complete resection and favorable histotypes are key predictors of long-term survival.
- The treatment strategy provides high survival rates with manageable recurrence rates.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.